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ABSTRACT
Purpose. To test the adequacy of the CVPP four-drug regimen as ancillary chemotherapy associat-
ed with extended-field radiotherapy in the treatment of early, unfavorable, clinically staged
Hodgkin’s disease.
Patients and Methods. The population of this prospective, multicenter study consisted of 49
patients with stage I-II disease, associated with bulky involvement or unfavorable histology (lym-
phocyte-depleted nodular sclerosis or lymphocyte depletion), systemic symptoms or extranodal
involvement, or presenting with stage III A favorable-histology disease, with or without extranodal
involvement.
Results. Complete remission was achieved in 39 patients, partial remission in 2, while 8 patients
did not respond. Four patients have relapsed so far (median follow-up: 43 months), all of whom
were subsequently rescued with different salvage treatments. Dose intensity (mean±SD: 0.83±0.12)
and hematological toxicity (including 2 deaths from infection) were higher when RT followed CT
than when it was interposed in the middle of the 6 cycles. No growth factors were used. Non-
hematological toxicity was very low and fully tolerable.
Conclusions. Results confirmed the mild neurological and gastroenteric side effects of CVPP that
make it an interesting MOPP-variant regimen. This combination seems most indicated when a regi-
men devoid of cardiac and pulmonary toxicity is required for association with full-dosage mediasti-
nal radiotherapy, as is often the case in early, unfavorable Hodgkin’s disease. The optimal sequence
consists of radiotherapy administered after completion of the chemotherapy program. The use of
growth factors for correction (or prevention) of marked leukopenia seems appropriate.
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S
tarting in 1988 the GISL treatment policy
for Hodgkin patients was differentiated
according to three prognostic categories: a)
patients with early disease and favorable presen-
tation; b) patients with early disease presenting
one or two unfavorable factors; c) cases with
advanced disease or very unfavorable presenta-
tion.
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At present, combined modality treatment
seems to be a reasonable choice for the interme-
diate-risk group in the opinion of many investi-
gators, as reviewed by Urba and Longo,1 Straus,2
DeVita and Hubbard,3 although various criteria
can be utilized to identify patients with early
disease and poorer prognosis.
MOPP (mechlorethamine, vincristine, pro-
carbazine, prednisone) chemotherapy, originally
designed for advanced stage disease,4 was also
the regimen of choice, together with its many
variants, in this subset of patients, who generally
received it in combination with radiotherapy.5-8
A large number of MOPP variant regimens were
tested in advanced or relapsed Hodgkin’s disease
in an attempt to reduce toxicity or improve
results,9 and in the 80’s these studies generated
some interest for regimens in which a nitrosurea
was substituted for nitrogen mustard, either car-
mustine (BCNU) as in BOPP,10 BVPP11 and
BCVPP,12 or lomustine (CCNU) as in CVPP,13
CEM14 and LVP.15
A MOPP variant using BCNU seemed to offer
even better results12 than MOPP itself, and alter-
native regimens with CCNU either gave more
prolonged remission and lower toxicity as first-
line therapy13 or achieved good remission rates
in relapsed patients;14,15 all of them were easy to
administered and well tolerated, resulting in
improved patient and physician compliance.
These data were confirmed by our Group on a
limited series of patients in a preliminary study
in which 6 cycles of CVPP (CCNU, vinblastine,
procarbazine, prednisone) were matched with
the same number of MOPP cycles in both early,
unfavorable disease – where they were com-
bined with extended-field radiotherapy – and in
advanced disease – where they were alternated
with 6 courses of ABVD (adriamycin, bleo-
mycin, vinblastine, dacarbazine).16
In 1988 CVPP in combination with extended-
field radiotherapy (EFRT) was chosen for a
prospective open study on the treatment of early
stage, unfavorable Hodgkin patients. The end-
points were a more detailed evaluation of the
toxicity and manageability of the regimen, pos-
sible confirmation of clinical results comparable
to the standards warranted by current combined
treatments involving four-drug chemotherapy
(MOPP, ABVD), and confirmation of acceptable
tolerance by the patients.
Materials and Methods
Between January 1988 and December 1993, 51
patients with early, unfavorable HD were regis-
tered for study by 12 GISL member institutions.
Patients were required to have biopsy-proven,
untreated Hodgkin’s disease with the following
staging features:  stage I-II with bulky involve-
ment (IXA-IIXA) or unfavorable histology (lym-
phocyte-depleted nodular sclerosis or lympho-
cyte depletion) or systemic symptoms (IB-IIB);
stage IA-IIIA with limited extranodal extension
(IEA-IIIEA); stage IIIA with histologic types
other than lymphocyte-depleted nodular sclero-
sis or lymphocyte depletion.  
Staging procedures were performed clinically,
according to the Cotswolds Meeting criteria.17
Besides careful physical examination, patients
underwent complete hematological and bio-
chemical screening, computed tomographic
scan of both chest and abdomen, bone marrow
core needle biopsy on one side. For patients
with B symptoms a second controlateral bone
marrow biopsy and ultrasound-guided liver and
spleen needle biopsies were also performed.
Lymphangiography was omitted. All the tests
performed at initial evaluation were repeated
after therapy with the exception of bone marrow
biopsy.
Two patients who continued receiving treat-
ment in non GISL centers were lost to follow-up
before the end of therapy and had to be exclud-
ed from the study. Thus the number of evalu-
able cases was 49.  No restrictions regarding per-
formance status or age were fixed, so the lowest
Karnofsky index was 30 and the oldest partici-
pant was 79. 
The CVPP regimen was scheduled every 4
weeks for a total of 6 cycles and consisted of
CCNU 75 mg/m2 given orally on day 1, vinblas-
tine (VBL) 4 mg/m2 injected intravenously on
days 1 and 8, procarbazine (PCZ) 100 mg/m2
and prednisone (Pred) 40 mg/m2 administered
orally from days 1 to 14. The criteria adopted
for dose modification according to toxicity were
those indicated by Cooper et al.13 If the leuko-
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cyte count was ≥ 43109/L and the platelet count
≥ 1003109/L, full dosage of CCNU, VBL and
PCZ was given. If the leukocyte count was
between 3 and 3.9993109/L or the platelet count
was between 75 and 993109/L, the doses of
CCNU, VBL and PCZ were reduced to 75%. If
WBC count fell between 2 and 2.9993109/L or
the platelets were between 50 and 743109/L,
CCNU, VBL and PCZ doses were reduced to
50%. If the WBC were < 23109/L and platelets
< 503109/L, the drugs were omitted until hema-
tological recovery occurred. 
Radiotherapy was administered by megavolt-
age equipment in 13 different divisions of radio-
therapy. The planned irradiation involved
subtotal lymphoid irradiation (STLI), including
mantle and para-aortic-splenic pedicle fields. In
the 6 patients with limited extralymphatic dis-
ease (stages IE-IIIE), the involved extralymphatic
organs were included in the irradiated fields.
Recommended dosage was 36 Gy (38 Gy on
bulky sites of involvement) but unavoidable dif-
ferences in source, energy, dose fraction, total
dose and field extension had to be tolerated
from institution to institution.
Complete remission (CR) was defined as com-
plete regression of measured lesions and disap-
pearance of all other objective evidence of lym-
phoma. Partial remission (PR) was defined as a
decrease in measurable lesions to less than 50%
of the sum of the products of the diameters of
measured lesions. No response (NR) was any
reduction less than partial remission.1 8
Progression (PG) was judged as an increase of
more than 25% in the sum of the products of
the diameters of measured lesions and/or the
appearance of new lesions. 
Dose intensity was calculated for each drug
and for the whole regimen according to the cri-
teria reported by Hryniuk19 and the examples
and suggestions furnished by DeVita et al.20
Toxicity was measured according to standard
Eastern Cooperative Oncology Group criteria.21
Standard techniques of one-way analysis of
variance were used to evaluate dose intensity
differences.22 Data regarding toxicity grades were
analyzed for possible differences with the Mann-
Whitney U test, considering the 0 to 4 grades of
toxicity as ranks of observations ordered with
increasing magnitude.22
Survival was measured from the date of diag-
nosis to the date of last observation or death.
Relapse-free survival (RFS) for complete
responders was calculated from the date of ther-
apy completion to the date of last observation or
relapse, while failure-free survival (FFS) was
measured from the date of start of therapy to
the date of disease progression, relapse (after
complete or partial remission) or death from
any cause. The overall survival and RFS curves
were calculated using the method of Kaplan and
Meier.23 Deaths due to causes other than HD or
therapy were not censored.
The trial was open and no comparisons
among treatments were planned; however, the
effectiveness and clinical adequacy of CVPP+EF
RT were indirectly checked through a compari-
son with  expected survival according to the
prognostic factors present at diagnosis, as
recorded in the International Database on
Hodgkin’s Disease (IDHD).24 The mathematical
model of survival of the IDHD, drawn from
5,023 patients treated with protocols used all
over the world in the 70’s and 80’s, was consid-
ered a good estimate of the standard patient
prognosis in relation to the individual clinical
characteristics at diagnosis and to the treatment
protocols used in recent decades.25
Results
The main clinical characteristics of the 49
study patients are recorded in Table 1. For 34 of
them subtotal nodal irradiation was interposed
between the third and fourth cycle of CT;  in 11
it followed the sixth cycle, while in 4 it was not
administered at all, either because of patient
refusal or clinical evidence of NR with a conse-
quent shift of the CT regimen. Thirty-nine sub-
jects achieved CR, 2 PR, and 8 did not respond
at all.
The mean relative dose intensity of the overall
regimen (mean of the doses of the three anti-
proliferative drugs received during n cycles over
planned doses, divided by the actual days of
administration for the same n cycles over
planned treatment duration) was 0.86±0.13. In
particular, it was 0.92±0.13 in the 15 patients
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with the treatment sequence CT (+RT),  and
0.83±0.12 in those treated with the sandwich
combination. This difference is statistically sig-
nificant (p = 0.0421) and closely related to the
higher frequency of dose reductions or adminis-
tration delays recorded during cycles 4 to 6 in
those patients who had RT interposed between
cycle 3 and 4 with respect to those who received
RT after the 6th CT cycle. Figure 1 illustrates this
phenomenon through the variation in dose
intensity recorded in each cycle for the three
antineoplastic drugs. It also shows that the
decrease in dose intensity during the last cycles
involved mainly CCNU and PCZ, which are the
most myelotoxic drugs in this regimen, while
VBL was affected very little. 
A total of 263 cycles were given, with a mean
of 5.4 per patients. Hematological toxicity on
the whole was considerable (see Table 2). Two of
the 4 patients with grade 3 anemia developed
transient hyporegenerative anemia and required
transfusion of concentrated erythrocytes; two
Total no. of patients 49
Sex                         male 28 female 21
Age             years    mean±SD 39.4±18.8 range 14 - 79
Performance status (Karnofsky index)
              median 90 range 30 - 100
Stage
I  A 4 I  B 1 III  A 5
IE A 2 II B 11 IIIE A 1
II  A 22 IIE B 2
IIE A 1
Histology
Lymphocyte predominance 5 Nodular sclerosis, lymphocyte depletion 6
Nodular sclerosis, undefined 13 Mixed cellularity 17
Nodular sclerosis, cellular phase 7 Lymphocyte depletion 1
Abdominal or mediastinal bulk 21/49
Hb (g/dL, mean±SD) 12.6±1.7 range 10.2-15.1
ESR (mm at 1hr, mean±SD) 48±35 range 3-116
LDH (mU/mL, mean±SD) 334±121 range 106-667
Table 1. Clinical characteristics
of the patients at diagnosis.
CT-RT CT-RT-CT Total
(15 pts) (34 pts) (49 pts)
Grades Hb WBC Plt Hb WBC Plt Hb WBC Plt
0 12 10 12 22 7 15 34 24 27
1 1 2 1 4 9 6 5 11 7
2 2 2 1 4 8 7 6 10 8
3 0 1 1 4 5 4 4 6 5
4 0 0 0 0 5 2 0 5 2
                           |--------------- 0.251 ------------------|
P                 |------------------  0.003  ---------------|
                                                  |------------------ 0.026 ---------------|
Table 2. Hematological toxicity
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others recorded grade 4 thrombocytopenia for a
few days without bleeding; 5 patients presented
grade 3 leukopenia (WBC < 1.9993109/L) and 5
grade 4 (WBC < 1.003109/L). In 6 cases these
episodes were febrile and were successfully treat-
ed with antibiotic therapy, without the adminis-
tration of growth factors. On the whole, the
hematological toxicity of CVPP was higher
when RT was interposed in the middle of the
regimen than when it was administered at the
end of it. In 8 of the patients treated with the
sandwich combination, drug delivery was
stopped at the fourth or fifth cycle because of
heavy and persistent leukopenia and/or throm-
bocytopenia. Differences in toxicity grades
recorded in the two treatment combinations
were statistically significant for both leukopenia
and thrombocytopenia, and patients generally
tended to complain of stronger hematological
toxicity when the 4th-6th CT cycles were adminis-
tered after RT rather than before it.  
Table 3 shows that nausea, vomiting, hair loss
and toxicity to both peripheral and autonomic
nerves were present but fully tolerable and had
no relationship to the timing of RT. One patient
suffered a loss of tendon reflexes with weakness
and difficulty in walking, while another com-
plained for a few days of obstipation and failure
to pass gas and showed abdominal distension.
Table 4 lists the less frequent side effects and
complications, together with the number of
patients who refused to continue therapy.
Bacterial and viral infections were clinically the
most serious or troublesome. Therapy was
stopped by patient request after 3 cycles in 1
case and after 4 cycles in another.
RT was administered in 45 patients; 3 subjects
did not respond after the first 3 cycles and were
admitted directly to salvage chemotherapy,
while 1 refused RT after completion of the 6 CT
cycles. RT was limited to mantle field in 18
cases, and consisted of STNI in the remaining
27. Patients were given RT with existing super-
voltage equipment in 13 different radiotherapy
units. Dose fractions varied from 0.17 to 0.22
Gy and total doses ranged from 30 to 47 Gy
(median 38.8). Early toxicity from RT was
recorded as mild myelosuppression in 3 patients
and as transient cutaneous alterations in 6. One
patient developed moderately severe postradia-
tion effusive pericarditis but recovered without
pericardiocentesis. 
Median follow-up is 52 months from the start
of therapy (range 14-83) and 43 months from
the end of it. Observed overall survival is illus-
trated in Figure 2, together with the survival
expected in the same group of patients accord-
ing to individual clinical pre-treatment charac-
teristics on the basis of the IDHD mathematical
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Figure 1. Mean relative single-drug dose intensity recorded for each cycle
of the CVPP regimen  in the 15 patients who received RT after the 6 CT
cycles (or had no RT at all), and in the 34 who received 3 CT cycles before
RT and 3 more after it. Reduction in drug dose intensity in cycles 4 to 6 is
more evident in patients treated with the sandwich technique.
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prognostic model (the figure reports the 67%
confidence band given by the expected mean ±
1 standard deviation). It is clear that observed
survival falls in the middle of the expected band
– and even in its upper half after the fourth or
fifth year – thus demonstrating that combined
CVPP chemotherapy and EF RT give at least
standard results according to the clinical experi-
ence of the last 25 years and in relation to prog-
nostic factors at diagnosis. Moreover, a trend
toward an apparent survival plateau can be
observed after 40 months. 
Figure 3 shows the failure-free survival curve
of the whole patient population and the relapse-
free survival curve of those 39 who achieved
complete remission. No response or disease pro-
gression during chemotherapy was recorded in
8 cases, 2 of whom were rescued by salvage ther-
apies, while 6 died with evidence of disease. In
all, 7 deaths and 4 relapses have been observed
in the whole population so far. The main char-
acteristics of these clinical failures are reported
in Table 5. One patient, a 51-year-old female
with stage I A disease, lymphocyte-depleted
nodular sclerosis histologic type, died of menin-
gitis caused by Escherichia coli without evidence
of disease after the fourth cycle of CT when her
neutrophil count fell to 0.23109/L. A second
patient, a 68-year-old male with stage IIIX A dis-
ease, mixed-cellularity histology, died of a hepa-
to-renal syndrome complicating long-standing
postnecrotic cirrhosis, 10 months after the end
of therapy; the liver disease had hampered cor-
rect administration of the CT regimen, to which
the lymphoma responded only partially.
Another male patient, 34 years old with stage II
A disease, mixed cellularity histologic type, who
showed a partial remission to CVPP was rescued
with 6 cycles of a 9-drug hybrid CT (MOPPEB-
VCAD) but died of hepatitis C virus without
evidence of disease a few months after complet-
ing therapy. An elderly female, aged 79, who had
been diabetic since her 60’s and suffering more
recently from atrial fibrillation, died suddenly of
CT-RT CT-RT-CT Total
(15 pts.) (34 pts) (49 pts)
Meningitis 1 1 2
Bacterial pneumonitis 0 2 2
H. zoster 0 5 5
Viral hepatitis (fatal) 1 0 0
Grade-2 toxic hepatitis 0 1 1
Hyporegenerative anemia 0 2 2
Epigastric pain due to PCZ 1 1 2
Refusal to continue CT 0 2 2
Refusal to undergo RT 1 0 1
Table 4. Less frequent side effects or complications related to CVPP
chemotherapy.
CT - RT CT - RT - CT Total
(15 pts.) (34 pts) (49 pts)
Grades N/V pNT vNT    H N/V pNT vNT H N/V pVT vNT H
0 10 14 14 12 16 28 30 25 26 42 44 37
1 2 1 1 1 6 2 1 2 8 3 2 3
2 3 0 0 2 11 3 2 6 14 3 2 8
3 0 0 0 0 1 1 1 1 1 1 1 1
4 0 0 0 0 0 0 0 0 0 0 0 0
                           |-------------- 0.185 ---------------|
                                  |---------------- 0.302 --------------|
  P                              |----------------- 0.548 ----------------|
                                                   |------------------ 0.582 ----------------|
Table 3. Main non hematological tox-
icity (ECOG grades) recorded during
administration of CVPP chemothera-
py  (Mann-Whitney U test). 
N/V= nausea and/or vomiting;  
pNT (peripheral neurotoxicity) =
paresthesia, decreased tendon
reflexes, motor loss; 
vNT (visceral neurotoxicity) = consti-
pation to paralytic ileus; 
H = hair loss.
probable cardiac causes after the third CT cycle,
when she was partially responding to therapy.
The remaining 3 deaths occurred from disease
progression in patients who had not responded
either to first-line or to salvage therapy.
There are no apparent common causes or pos-
sible explanations for these failures. Three
patients (cases 3, 5 and 8) received under-
dosages of the regimen, mainly due to concomi-
tant pathologies. In all but 3 patients (cases 2, 6
and 9) age was rather advanced. Those patients
who did not respond at all to the first few cycles
of CVPP also failed with salvage CT, whereas all
the ones who relapsed were rescued with MOPP
(mechlorethamine, vincristine, procarbazine
and prednisone) or alternating MOPP/ABVD
(MOPP/adriamycin, bleomycin, vinblastine and
decarbazine) or hybrid MOPPEBVCAD  CT.
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Figure 2. Observed overall survival of the 49 study patients compared with
expected survival on the basis of individual clinical staging determinants


















Figure 3. Failure-free survival of the whole population treated with com-
bined CVPP + RT and relapse-free survival of the 39 patients who
achieved complete remission. 
Sex Age Stage Histology No. of CT RT Response Comments
cycles DI Fields (Gy)
1 F 51 I A NS 4 1.00 not done CR Died of meningitis
2 M 34 II A MC 6 .87 not done PR* Died of hepatitis in CR
3 M 68 IIIXA MC 3 .73 STLI (36) PR Died of cirrhosis
4 F 79 II A NS 3 1.04 not done PR Died suddenly #
5 F 74 IIXA      NS (LD) 3 .78 not done NR Died in PG
6 M 28 IIXA LD 3 .89 Mantle (38) NR Died in PG
7 M 53 II B NS (LD) 3 .86 STLI (40) NR Died in PG
8 M 60 IIXA MC 6 .75 Mantle (42) CR Relapsed at 6 mo.
9 M 23 I A MC 6 .92 Mantle (40) CR Relapsed at 14 mo. §
10 M 57 IIXA MC 6 .86 Mantle (36) CR Relapsed at 18 mo. §
11 M 65 IIXA LP 6 .80 Mantle (36) CR Relapsed at 56 mo.
Table 5. Clinical characteristics of the patients who died of any cause or relapsed.
*PR to CVPP, then rescued to CR by salvage chemotherapy; #sudden death of probable cardiac origin; long-standing diabetes mellitus and chronic atrial fibrillation coexisted; √con-
comitance of silicosis; §relapses outside the irradiated areas.
So far, no myelodysplastic syndromes or overt
second cancers have been found. Fertility was
not specifically studied; nevertheless, it is known
to have been preserved in some of these
patients. A 29-year-old and a 36-year old man
have both fathered children since treatment.
Discussion
The 1987 GISL decision to divide HD patients
into 3 categories according to different staging
characteristics with different therapeutic
requirements was based on the identification of
an intermediate-risk group between patients
with early disease and favorable presentation,
who could be treated with RT alone or com-
bined with a low-toxicity CT regimen, and those
with advanced disease, who require a CT regi-
men with 7 or 8 drugs – or even more – possibly
followed by very limited RT on sites of major
involvement.
The allocation of early disease patients pre-
senting bulky involvement or unfavorable histo-
logic type or B symptoms or localized extran-
odal involvement to this intermediated-risk
group proved to be a reasonable choice on clini-
cal grounds. The IDHD prognostic estimation
criteria, drawn from a very large international
population of patients who received standard
staging and treatment in the 70’s and 80’s, now
demonstrate that this group of patients with
early disease and unfavorable presentation
shows a 0.72±0.18 probability of surviving at 10
years, which is indeed intermediate between
that of the early and favorable disease group
(0.81±0.13) and that of the advanced one (0.60
±0.20). 
While STNI and VBM (vinblastine, bleomycin
and methotrexate) CT were considered ade-
quate in the most favorable subset,26 and the
MOPPEBVCAD hybrid was an interesting solu-
tion for the worst prognostic group,27 there was
a general consensus that four-drug CT followed
by EF RT would be the best approach for the
intermediate prognosis patients. However, a
high incidence of bulky mediastinal masses that
required using large RT fields and additional
local boosts advised against associating CT regi-
mens containing bleomycin and adriamycin,
which would have increased the risk of pul-
monary and cardiac toxicity, respectively. So,
after the hypothesis of ABVD or ABVD-like reg-
imens had been discarded because of their
potential cardiac and pulmonary side effects,
MOPP or MOPP-like CT remained the most
effective alternate solution. The definitive choice
of CVPP was determined by the following con-
siderations:
a) in the 80’s the interminable search for more
effective or less toxic (or both) MOPP-derivative
regimens seemed to converge on the usefulness
of substituting a nitrosurea for nitrogen mus-
tard. Bakemeier et al.12 obtained the same CR
rate with MOPP (73%) and BCVPP (BCNU,
cyclophosphamide, vinblastine, procarbazine
and prednisone), as well as a significantly longer
remission duration and overall survival for the
patients treated with BCVPP. Cooper et al.13 in
an accurate and elegant clinical trial on 566
patients demonstrated that of MOPP and 3
other MOPP-derived regimens – MVPP (vin-
blastine for vincristine), COPP (CCNU for
nitrogen mustard) and CVPP (CCNU for nitro-
gen mustard and vinblastine for vincristine) –
this last was superior in efficacy and reduced
toxicity, and that the use of CCNU was the most
significant determinant of prolonged remis-
sions;
b) at the same time CCNU was also receiving
increasing attention as an effective agent in
many multiple drug salvage regimens, such as
CVB28 (CCNU, vinblastine  and bleomycin),
SCAB29 (streptozotocin, CCNU, doxorubicin
and bleomycin) and LVB15 (lomustine, vindesine
and bleomycin);
c) a favorable prior experience with CVPP was
already available to the GISL,16 one that con-
firmed the good results, low toxicity and even
better patient compliance than with MOPP.
As far as clinical results are concerned, an 80%
CR rate with a 10% relapse rate after a nearly 4-
year median follow-up, with projected 5-year
survival of 85% must be considered good over-
all results, somewhat better (see Figure 2) than
those expected on the basis of individual pre-
treatment characteristics according to the IDHD
mathematical model. In particular, the estimates
drawn from the IDHD were based on a pool of
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patients treated with RT alone or with single or
bi-agent chemotherapy in 63% of stage I-II
cases and in 26% of stage III A cases, while 37%
of stage I-II and 74% of stage III A patients were
treated with multiple drug chemotherapy
(MOPP or ABVD) with or without RT. There-
fore we can conclude that early and intermedi-
ate results are at least comparable to those
achieved with the combination of chemo- and
radiotherapy used in recent decades; moreover,
the trend toward a higher survival plateau than
that of the mean estimates after the fourth year
is of some interest in light of the greater fre-
quency of long-lasting remissions claimed to be
produced by CVPP chemotherapy.     
Gastroenteric toxicity was mild and fully con-
trolled with metoclopramide, alizapride or
prochlorperazine, without the need for HT3
antagonists. Neurotoxicity was slight and easily
manageable. No pulmonary toxicity was record-
ed and this strengthens the idea that, even
though CCNU is considered potentially toxic to
the lungs, this toxicity does not manifest itself at
the usual dosages employed for the treatment of
lymphomas, nor does the drug significantly
enhance the toxicity linked to RT on the medi-
astinum.
Infectious complications were a relatively
major problem (see Table 4). This is in agree-
ment with the observations of Cooper et al.,13
who correlated an increased frequency of infec-
tions with the use of vinblastine in patients over
60 years of age. As a matter of fact, 20% of our
patients were over 60 and most of the infective
episodes actually did involve this group.
However, we believe that the prolonged bone
marrow depression related to CCNU may also
be implicated along with VBL dosage and
advanced age. This is reflected by the greater
reduction in CCNU dose intensity that became
necessary in most of these patients.
We must point out that a higher frequency of
hematological toxicity and infectious complica-
tions is commonly observed when CT is com-
bined with extended RT. This is particularly evi-
dent when the former follows the latter, even if
only a part of the CT regimen is delivered after
RT, as was the case for the majority of these
patients. For this reason the sandwich adminis-
tration of CVPP, partly before and partly after
RT, has to be abandoned in favor of a schedule
in which CT is given entirely before RT. It is
noteworthy that no use of growth factors was
made throughout the trial. We simply reduced
the VBL, CCNU and PCZ doses whenever
hematologic toxicity became apparent, accord-
ing to the suggestions of Cooper et al.,13 and
adopted oral antibacterial prophylaxis whenever
neutrophil counts dropped below 0.53109/L
(cotrimoxazole or a chinolonic derivative). The
present availability of G- or GM-CSF,30,31 admin-
istered either therapeutically or even prophylac-
tically, would easily solve this problem.
The good results achieved and the mild toxici-
ty recorded, whether absolutely low or easily
reducible, make the CVPP regimen the MOPP-
derivative of choice for those patients in whom
heavy mediastinal RT programs or concomitant
pulmonary or cardiac diseases would con-
traindicate the use of bleomycin- and adri-
amycin-containing regimens. Its delivery before
RT, together with strict therapeutical use of
growth factors, is recommended.   
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